Fosaprepitant Injection, Powder, Lyophilized, For Solution
Product Images NDC 72162-2636

Product Visual Gallery

This gallery contains 3 technical images submitted to the FDA as part of the official labeling for Fosaprepitant (NDC 72162-2636). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Extended Label (72162 2636 02extendedlabel)

This is a description of a sterile lyophilized powder that is intended for intravenous use only after reconstitution and dilution. It warns against using it with solutions that contain divalent cations such as calcium (Ca2+) and magnesium (Mg2+), including lactated Ringer's solution and Hartmann's solution.*

FDA Label Image

Str (Fosaprepitant Structure)

FDA Label Image

Label (Lbl721622636)

This text provides information about a medication called Fosaprepitant in the form of an injection solution. Each vial contains 150 mg of Fosaprepitant, equivalent to 245.3 mg fosaprepitant dimeglumine, along with various inactive ingredients. The drug solution must be reconstituted with 5 mL of 0.9% Sodium Chloride. The reconstituted solution is stable for 24 hours at room temperature. It is recommended to refrigerate the vial at 2°C - 8°C and discard any unused portion. The usual dosage and detailed preparation instructions can be found by scanning the package insert QR code.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.